NDA 212279 · Giskit
Exem Foam Kit
Air Polymer-Type A · Intrauterine
NovelLast checked: Nov 20, 2026Latest source record: Nov 7, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Nov 7, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
8
1 Phase 3, 2 recruiting
FAERS reports
2
2 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 8, 2023.
ExEm ® Foam is indicated for sonohysterosalpingography to assess fallopian tube patency in women with known or suspected infertility. ExEm ® Foam is an ultrasound contrast agent indicated for sonohysterosalpingography to assess fallopian tube patency in women with known or suspected infertility. ( 1 )
Mechanism: ExEm Foam (air polymer-type A) intrauterine foam is formed by mixing the clear Gel [polymer-type A (hydroxyethyl cellulose), glycerin, and purified water] with air and Sterile Purified Water, creating an echogenic contrast agent. When visualized with ultrasound, the foam appears echogenic or bright within the fallopian tubes and peritoneal cavity.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- EXEM FOAM KIT · AIR POLYMER-TYPE A 10ML · FOAM, INTRAUTERINE · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Air Polymer A" as an intervention, any sponsor and status, largest first.
- The Effectiveness of Simethicone In Improving Visibility During ColonoscopyPivotal-lookingCompleted
Ramathibodi HospitalAcademic, hospital or other
NCT00615303 · 194 participants · Start Dec 2006 · Primary completion Dec 2007
Drug: Simethicone; Placebo · For: Colonoscopy
Sites: Bangkok, Thailand
- Effect of Simethicone on Reducing Bowel Interference During Tubal ResectionPivotal-lookingCompleted
Chiang Mai UniversityAcademic, hospital or other
NCT03429621 · 120 participants · Start Mar 8, 2018 · Primary completion Feb 28, 2019
Drug: Simethicone 80 MG · For: Sterility, Postpartum
Sites: Chiang Mai, Thailand
Mersin UniversityAcademic, hospital or other
NCT06765330 · 78 participants (planned) · Start May 5, 2025 · Primary completion Aug 29, 2025
Drug: CHX disinfection · For: Dental Caries
Sites: Mersin, Turkey (Türkiye)
- Foam Sclerotherapy With or Without Transdermal Laser for Reticular Veins and TelangiectasiasRecruiting
University of Sao PauloAcademic, hospital or other
NCT07793630 · 70 participants (planned) · Start Sep 1, 2026 · Primary completion Feb 2027
Drug: Polidocanol foam sclerotherapy · For: Telangiectasias; Reticular Veins; Chronic Venous Disease
Sites: Ribeirão Preto, Brazil
- Different Luting Cements for Pediatric Zirconia CrownsNot yet recruiting
Cairo UniversityAcademic, hospital or other
NCT07152561 · 60 participants (planned) · Start Aug 28, 2025 · Primary completion Aug 28, 2026
Drug: Zirconia crown cemented with Predicta® Bioactive Cement; Zirconia crown cemented with resin-cement · For: Dental Caries in Children
Dow University of Health SciencesAcademic, hospital or other
NCT04754763 · 52 participants · Start Jun 1, 2018 · Primary completion May 31, 2019
Drug: Dentin-Bonding Agents; Propolis · For: Dentine Hypersensitivity
Sites: Karachi, Pakistan
Al-Azhar UniversityAcademic, hospital or other
NCT07065305 · 21 participants (planned) · Start Sep 15, 2025 · Primary completion Sep 15, 2026
Drug: Curodont Repair Fluoride Plus (Self-assembling peptide remineralization agent)P11-4 peptide, fluoride, mild acidic buffer (pH ~4.5) , Credentis AG, Switzerland; Beautifil II LS · For: Remineralization Potential; Dentin Caries
University of PaviaAcademic, hospital or other
NCT07088679 · 20 participants (planned) · Start Jul 30, 2025 · Primary completion Dec 1, 2026
Drug: Sterify Gel (mucoadhesive bioactive gel) · For: Peri-implantitis; Dental Implants; Non-surgical Periodontal Therapy
Sites: Pavia, Italy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- epilepsy1
- peritoneal disorder1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 1 |
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Giskit
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.